Skip to main content
See every side of every news story
Published loading...Updated

NRx targets 2026 KETAFREE approval and outlines SPARC-TMS trial in 400 patients backed by military funding (NASDAQ:NRXP)

Summary by Seeking Alpha
NRx Pharma (NRXP) Q2 2026 earnings call recap: KETAFREE ANDA update, DARPA SPARC-TMS trial, NRX-100 NDA path, cash runway—read now.

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in Ra'anana, Israel on Tuesday, August 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal